Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-10

Clinical Trial Update: ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) [Phase 3]

View source ↗

Summary

Phase 3 trial ESSENCE 2 evaluating CyclASol for dry eye disease has completed and results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CyclASol (cyclosporine A)

Snippet

Sponsor: Novaliq GmbH | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-03-10